Takara Bio Inc. revised consolidated earnings guidance for the year ending March 31, 2024. For the year ending March 31, 2024, the company expects net sales of JPY 45,500 million compared to previous guidance of JPY 53,300 million, operating profit of JPY 3,000 million compared to previous guidance of JPY 8,000 million and net income attributable to owners of parent of JPY 2,000 million or JPY 16.61 per share compared to previous guidance of JPY 5,500 million or JPY 45.67 per share.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,021 JPY | -1.45% | -5.99% | -18.45% |
05-10 | Takara Bio Inc. Proposes Dividend for the Fiscal Year Ending March 31, 2024, Effective June 24, 2024 | CI |
03-18 | Takara Bio Inc.(TSE:4974) dropped from FTSE All-World Index | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.45% | 794M | |
+64.92% | 62.86B | |
-1.85% | 41.38B | |
+44.76% | 40.38B | |
-8.93% | 27.64B | |
+13.05% | 26.46B | |
-21.96% | 18.9B | |
+4.21% | 12.67B | |
+25.74% | 12.27B | |
+27.42% | 12.07B |
- Stock Market
- Equities
- 4974 Stock
- News Takara Bio Inc.
- Takara Bio Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024